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Abstract
Background
Critically ill patients have considerable oxidative stress. Glutamine and antioxidant 
supplementation may offer therapeutic benefit, although current data are conflicting.
Methods
In this blinded 2-by-2 factorial trial, we randomly assigned 1223 critically ill adults 
in 40 intensive care units (ICUs) in Canada, the United States, and Europe who had 
multiorgan failure and were receiving mechanical ventilation to receive supple-
ments of glutamine, antioxidants, both, or placebo. Supplements were started within 
24 hours after admission to the ICU and were provided both intravenously and en-
terally. The primary outcome was 28-day mortality. Because of the interim-analysis 
plan, a P value of less than 0.044 at the final analysis was considered to indicate 
statistical significance.
Results
There was a trend toward increased mortality at 28 days among patients who re-
ceived glutamine as compared with those who did not receive glutamine (32.4% vs. 
27.2%; adjusted odds ratio, 1.28; 95% confidence interval [CI], 1.00 to 1.64; P = 0.05). 
In-hospital mortality and mortality at 6 months were significantly higher among 
those who received glutamine than among those who did not. Glutamine had no 
effect on rates of organ failure or infectious complications. Antioxidants had no ef-
fect on 28-day mortality (30.8%, vs. 28.8% with no antioxidants; adjusted odds ratio, 
1.09; 95% CI, 0.86 to 1.40; P = 0.48) or any other secondary end point. There were no 
differences among the groups with respect to serious adverse events (P = 0.83).
Conclusions
Early provision of glutamine or antioxidants did not improve clinical outcomes, and 
glutamine was associated with an increase in mortality among critically ill patients 
with multiorgan failure. (Funded by the Canadian Institutes of Health Research; 
ClinicalTrials.gov number, NCT00133978.)
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Critically ill patients have oxida-tive stress. The most seriously ill patients in intensive care units (ICUs) have in-
creased mediators of oxidant stress and a higher 
incidence of multiorgan failure than less seriously 
ill patients.1-5 Meta-analyses of randomized trials 
suggest that glutamine and antioxidant supple-
mentation in critically ill patients may be associ-
ated with improved survival.6,7 However, recent 
large studies have not confirmed such an effect.8,9 
The objective of the present trial was to evaluate 
the effect of early glutamine and antioxidant sup-
plementation in critically ill patients. Our a priori 
hypothesis was that supplementation with these 
nutrients would reduce 28-day mortality.
Methods
Study Participants
Consecutive adults who were receiving mechani-
cal ventilation and who were admitted to partici-
pating ICUs were screened for eligibility. Patients 
were included if they had two or more organ fail-
ures related to their acute illness. A complete list 
of the eligibility criteria is included in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org.
Study Design and Interventions
Using a factorial design, we randomly assigned 
patients to receive glutamine supplementation 
(0.35 g per kilogram of body weight per day in-
travenously according to ideal body weight, pro-
vided as 0.50 g of the dipeptide alanyl-glutamine 
[Dipeptiven, Fresenius Kabi] per kilogram per day 
given intravenously and 42.5 g of alanyl-glutamine 
and glycine-glutamine dipeptides, which provide 
30 g of glutamine, per day given enterally) or 
matching placebo solutions. In addition, patients 
were randomly assigned to receive 500 μg of sele-
nium intravenously (Selenase, Biosyn) plus the fol-
lowing vitamins and minerals enterally: 300 μg 
of selenium, 20 mg of zinc, 10 mg of beta carotene, 
500 mg of vitamin E, and 1500 mg of vitamin C. 
The control group received placebo intravenously 
plus placebo enterally. Study-group assignments 
were concealed and stratified according to site 
with the use of permuted blocks of random size 
and a secure central Web-based system.
To maintain blinding, study supplements and 
placebos were prepared by an unblinded local 
study pharmacist and delivered as masked solu-
tions to the ICU. The administration of all study 
solutions was initiated as soon as possible after 
randomization; the solutions were administered 
separately from standard nutrition, were provided 
continuously, and were administered for a maxi-
mum of 28 days, until discharge from the ICU 
or death. All patients were fed according to the 
Canadian Critical Care Nutrition practice guide-
lines, independently of the study supplements.10 
All other management decisions were at the dis-
cretion of the ICU team.
The primary outcome was 28-day mortality. 
Secondary outcomes and data collected in this 
trial are described in the Supplementary Appen-
dix. In a sample of patients enrolled at seven sites 
in North America, blood was drawn at baseline, 
day 4, and day 7 for measurement of plasma glu-
tamine and selenium levels according to standard 
techniques.
Study Oversight
This investigator-initiated trial was designed by 
the first author in consultation with the steering 
committee. The steering committee vouches for 
the data, the analysis, and the decision to submit 
the manuscript for publication. All sites listed in 
the acknowledgments in the Supplementary Ap-
pendix participated in the data collection. The last 
author was responsible for the analysis. The first 
author and the writing committee wrote the man-
uscript. The protocol was endorsed and conduct-
ed in collaboration with the Canadian Critical 
Care Trials Group.
The study was funded by the Canadian Insti-
tutes of Health Research. Fresenius Kabi provided 
the glutamine supplements and an unrestricted 
grant-in-aid. Biosyn provided the intravenous 
selenium to all participating European sites. 
None of these agencies had a decision-making 
role in the design or conduct of the study, analy-
sis or interpretation of data, manuscript prepa-
ration, or decision to submit the manuscript for 
publication.
The study was conducted according to the pro-
tocol, which has been published previously9,11,12 
and is available at NEJM.org. This trial was con-
ducted between April 2005 and December 2011 
in 40 ICUs in participating countries after ap-
proval by local jurisdictional and institutional 
research ethics boards. Written informed consent 
was obtained from all patients or their legal 
representatives before enrollment.
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Statistical Analysis
Data were analyzed according to the protocol, 
which included details of the sample-size justifi-
cation, the interim analyses, and the final analytic 
plan.12 In brief, assuming a 28-day mortality of 
30%, we planned to enroll 1200 patients who 
could be evaluated in order to provide 80% power 
if either intervention (or both interventions) re-
sulted in a 25% relative risk reduction, to 22.5%. 
Because of two planned interim analyses, a P value 
of less than 0.044 at the final analysis was con-
sidered to indicate statistical significance.
In accordance with the intention-to-treat 
principle, all patients were included in the group 
to which they were randomly assigned. In addi-
tion, a prespecified efficacy analysis that in-
cluded only patients who received a study agent 
for a minimum of 5 days was conducted. In the 
prespecified primary outcome assessment, we 
used logistic regression with terms for the pres-
1223 Underwent randomization
5633 Patients were assessed for eligibility
4410 Were excluded
3350 Did not meet eligibility criteria
1045 Were admitted to ICU after 24 hr
518 Had absolute contraindication to enteral nutrients
419 Had severe acquired brain injury
295 Were not expected to stay in ICU >48 hr
237 Had Child–Pugh class C cirrhosis
238 Lacked commitment to full aggressive care
163 Had life expectancy of <6 mo
142 Had seizure disorder requiring anticonvulsant
95 Underwent routine elective cardiac surgery
81 Weighed <50 kg or >200 kg
70 Were enrolled in related ICU interventional study
19 Were pregnant or lactating with intent to breast-feed
15 Had diagnosis of burns (≥30% BSA) at primary
admission
9 Underwent previous randomization in the study
1 Was <18 yr of age
3 Had other reasons
1060 Were eligible, but did not undergo randomization
471 Did not have family present
233 Declined to participate
180 Were expected to stay in ICU <5 days
82 Were overlooked by investigators
39 Were withdrawn by physician
55 Had other reasons
302 Were assigned to
receive placebo
310 Were assigned to receive
antioxidants plus glutamine
1 Withdrew consent
before initiation of
study supplements
1 Withdrew consent
after 3 days on study
300 Were included in the
primary analysis
310 Were included in the
primary analysis
303 Were assigned to
receive glutamine
2 Withdrew consent
before initiation of
study supplements
301 Were included in the
primary analysis
308 Were assigned to
receive antioxidants
1 Withdrew consent
before initiation of
study supplements
307 Were included in the
primary analysis
Figure 1. Study Enrollment and Randomization.
BSA denotes body-surface area, and ICU intensive care unit.
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ence or absence of cardiovascular dysfunction, 
both study agents, and their interaction. The in-
teraction term was dropped when it was not sig-
nificant. We included odds ratios and 95% con-
fidence intervals in the comparison of 28-day 
mortality for each intervention, both overall and 
separately, in the presence and absence of the 
other intervention.13 Finally, we conducted anal-
yses involving prespecified subgroups, as de-
scribed in the Supplementary Appendix.
For all analyses of secondary outcomes, we 
performed separate comparisons of the two groups 
that received glutamine with the two groups that 
did not receive glutamine and the two groups that 
Table 1. Baseline Characteristics of the Study Patients.*
Characteristic Placebo (N = 300) Glutamine (N = 301) Antioxidants (N = 307)
Antioxidants plus  
Glutamine (N = 310)
Age — yr 62.8±13.7 (18.0–89.0) 62.5±15.0 (19.0–91.5) 63.6±14.3 (18.0–92.0) 64.3±14.0 (22.0–92.9)
Sex — no. (%)
Female 122 (40.7) 110 (36.5) 130 (42.3) 130 (41.9)
Male 178 (59.3) 191 (63.5) 177 (57.7) 180 (58.1)
BMI — range† 29.9±8.3 (17.9–63.1) 29.9±8.9 (16.7–70.4) 29.2±7.9 (15.8–68.5) 30.1±8.6 (15.8–78.3)
APACHE II score — range‡ 26.0±7.4 (6.0–49.0) 26.6±7.6 (8.0–48.0) 25.9±7.1 (9.0–51.0) 26.8±7.4 (10.0–49.0)
Charlson comorbidity index score — range§ 1.7±1.8 (0.0–8.0) 1.5±1.6 (0.0–8.0) 1.8±1.8 (0.0–10.0) 1.8±1.8 (0.0–11.0)
Functional comorbidity index score — range¶ 1.5±1.4 (0.0–6.0) 1.4±1.4 (0.0–7.0) 1.5±1.4 (0.0–6.0) 1.5±1.3 (0.0–7.0)
Admission category — no. (%)
Medical 236 (78.7) 238 (79.1) 254 (82.7) 235 (75.8)
Surgical
Elective 26 (8.7) 27 (9.0) 19 (6.2) 35 (11.3)
Emergency 38 (12.7) 36 (12.0) 34 (11.1) 40 (12.9)
Primary ICU diagnosis — no. (%)
Cardiovascular or vascular disorder 70 (23.3) 54 (17.9) 53 (17.3) 60 (19.4)
Respiratory disorder 97 (32.3) 101 (33.6) 94 (30.6) 83 (26.8)
Gastrointestinal disorder 17 (5.7) 21 (7.0) 32 (10.4) 25 (8.1)
Neurologic disorder 2 (0.7) 4 (1.3) 5 (1.6) 2 (0.6)
Sepsis 86 (28.7) 88 (29.2) 98 (31.9) 106 (34.2)
Trauma 10 (3.3) 9 (3.0) 5 (1.6) 7 (2.3)
Metabolic disorder 6 (2.0) 8 (2.7) 9 (2.9) 5 (1.6)
Hematologic disorder 0 2 (0.7) 0 4 (1.3)
Renal disorder 0 2 (0.7) 0 5 (1.6)
Gynecologic disorder 1 (0.3) 0 0 0
Orthopedic disorder 0 1 (0.3) 2 (0.7) 3 (1.0)
Other disorder 11 (3.7) 11 (3.7) 9 (2.9) 10 (3.2)
Cause of shock — no. (%)
Cardiogenic 72 (24.0) 54 (17.9) 57 (18.6) 57 (18.4)
Septic 191 (63.7) 206 (68.4) 218 (71.0) 211 (68.1)
Neurogenic 2 (0.7) 3 (1.0) 3 (1.0) 2 (0.6)
Anaphylactic 0 1 (0.3) 1 (0.3) 0
Hemorrhagic 13 (4.3) 10 (3.3) 9 (2.9) 16 (5.2)
Unknown 11 (3.7) 15 (5.0) 13 (4.2) 14 (4.5)
Other 2 (0.7) 3 (1.0) 2 (0.7) 5 (1.6)
Not in shock 9 (3.0) 9 (3.0) 4 (1.3) 5 (1.6)
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received antioxidants with the two groups that did 
not receive antioxidants. Counts and percentages 
are presented for categorical variables, medians 
and quartiles for skewed variables, and means, 
standard deviations, and ranges for other con-
tinuous variables. In particular, the quartiles for 
the duration of mechanical ventilation and of 
ICU and hospital stays were estimated with a 
Kaplan–Meier analysis in which data on patients 
who died before (or within 24 hours after) reach-
ing these discharge or discontinuation events 
were censored after the end of follow-up (after all 
event times); death was thereby treated as an event 
that precluded the possibility of discharge or 
discontinuation of mechanical ventilation. We 
also reported length-of-stay variables with death 
treated as a discharge in patients who died be-
fore discharge. Survival rates up to 6 months are 
shown with the use of Kaplan–Meier curves and 
compared with the use of the Wald test from the 
Cox proportional-hazards model, with terms for 
each study-agent intervention and the presence or 
absence of cardiovascular dysfunction at base-
line. Data on patients whose vital status was un-
known at 6 months were censored on the date 
they were last known to be alive.
Table 1. (Continued.)
Characteristic Placebo (N = 300) Glutamine (N = 301) Antioxidants (N = 307)
Antioxidants plus 
Glutamine (N = 310)
Inclusion criteria — no. (%)
PaO2:FiO2 ratio ≤300 282 (94.0) 285 (94.7) 287 (93.5) 285 (91.9)
Clinical evidence of hypoperfusion 277 (92.3) 278 (92.4) 286 (93.2) 293 (94.5)
Renal dysfunction 104 (34.7) 117 (38.9) 99 (32.2) 122 (39.4)
Platelet count ≤50×109/liter 16 (5.3) 21 (7.0) 12 (3.9) 18 (5.8)
Duration of ICU stay before randomization — hr
Median 17.9 17.7 18.4 18.0
Interquartile range 13.4–21.5 12.7–21.1 12.3–21.5 13.3–21.6
No. of failed organs — no. (%)‖║
1 1 (0.3) 2 (0.7) 1 (0.3) 0
2 221 (73.7) 206 (68.4) 236 (76.9) 216 (69.7)
3 76 (25.3) 85 (28.2) 69 (22.5) 90 (29.0)
4 2 (0.7) 8 (2.7) 1 (0.3) 4 (1.3)
Time from first organ dysfunction — hr
To initiation of enteral supplements
Median 23.0 21.4 21.5 21.7
Interquartile range 17.0–27.3 15.9–26.4 16.8–26.0 17.0–27.0
To initiation of parenteral supplements
Median 22.3 21.0 21.1 21.5
Interquartile range 16.5–26.5 14.8–25.0 16.0–25.5 16.3–26.0
To initiation of enteral nutrition
Median 22.0 21.0 20.4 20.0
Interquartile range 12.5–36.8 11.1–35.0 12.0–34.8 11.8–36.2
* Plus–minus values are means ±SD. FiO2 denotes fraction of inspired oxygen, ICU intensive care unit, and PaO2 partial pressure of arterial 
oxygen.
† The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
‡ The Acute Physiology and Chronic Health Evaluation II (APACHE II) score ranges from 0 to 71, with higher scores indicating more severe 
disease.
§ The score on the Charlson comorbidity index reflects a weighted sum of 17 medical conditions; scores range from 0 to 37, with higher scores 
indicating a greater burden of illness.
¶ Scores on the functional comorbidity index range from 0 to 18, with higher scores indicating a greater burden of illness.
║‖ Organ failures were defined according to the same criteria used for enrollment.
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Results
Patients
We screened 5633 patients; 2283 were eligible, and 
1223 were enrolled (Fig. 1). An additional 23 pa-
tients were enrolled to compensate for randomly 
assigned patients who did not receive study sup-
plements because of early death, ICU discharge, 
or withdrawal from the trial. Five randomly as-
signed patients could not be evaluated because we 
could not ascertain their 28-day vital status; thus, 
there were 1218 patients in the final intention-to-
treat analysis. There were no significant differ-
ences in baseline characteristics among the four 
groups (Table 1). Data on the timing and amount 
of study supplements and the amount of nutri-
tion received are provided in Table 1 in the Sup-
plementary Appendix. Overall, patients received 
70.9% of enteral study supplements and 89.1% of 
parenteral study supplements prescribed.
Primary Outcome
The overall 28-day mortality was 29.8% (95% 
confidence interval [CI], 27.2 to 32.5). At 28 days, 
there was a trend toward increased mortality 
among patients who received glutamine as com-
pared with patients who did not receive gluta-
mine (32.4% vs. 27.2%; adjusted odds ratio, 1.28; 
95% CI, 1.00 to 1.64; P = 0.05) (Table 2). There was 
no significant difference in mortality between 
patients who received antioxidant supplementa-
tion and patients who did not receive antioxi-
dants (30.8% and 28.8%, respectively; adjusted 
odds ratio, 1.09; 95% CI, 0.86 to 1.40; P = 0.48). 
There was no significant interaction between 
glutamine and antioxidants (P = 0.49) (Table 2). 
In the efficacy analysis, the estimate of effects 
did not change significantly for glutamine versus 
no glutamine (odds ratio, 1.20; 95% CI, 0.89 to 
1.62; P = 0.23) or for antioxidants versus no anti-
oxidants (odds ratio, 0.98; 95% CI, 0.73 to 1.32; 
P = 0.90). There were no significant differences in 
28-day mortality in any of our a priori subgroup 
analyses in the intention-to-treat analysis (Fig. 2) 
or the efficacy analysis comparing the effect of the 
different study supplements on 28-day mortality 
(data not shown), and no tests for between-sub-
group heterogeneity showed significance (P>0.05 
for interaction for all tests).
Secondary Outcomes
In-hospital mortality and mortality at 6 months 
were significantly higher among patients who 
received glutamine than among patients who did 
not receive glutamine (Table 3, and Fig. 1 in the 
Supplementary Appendix). There were also sig-
nificant increases in the median time to dis-
charge alive from the ICU and the median time 
to discharge alive from the hospital among pa-
tients who received glutamine as compared with 
those who did not (Table 3). For outcomes in the 
four individual study-agent groups, see Table 2 in 
the Supplementary Appendix. Glutamine supple-
mentation as compared with no glutamine did not 
Table 2. Odds Ratio for Death According to Study Agent.*
Variable Antioxidants
Glutamine-Specific 
Odds Ratio with  
Antioxidants (95%)
Overall Adjusted  
Odds Ratio with  
Antioxidants (95% CI) P Value
Yes No
Glutamine 1.09 (0.86–1.40) 0.48
Yes — no. of patients who died/total no. (%) 101/310 (32.6) 97/301 (32.2) 1.02 (0.72–1.43)
No — no. of patients who died/total no. (%) 89/307 (29.0) 76/300 (25.3) 1.20 (0.84–1.72)
Antioxidant-specific odds ratio with glutamine  
(95% CI)
1.18 (0.83–1.66) 1.40 (0.98–2.00)
Overall adjusted odds ratio with glutamine  
(95% CI)
1.28 (1.00–1.64) 0.05†
* The overall adjusted odds ratios are the estimates of the pooled effect of each study agent, controlled for other study agents; this is the pri-
mary outcome. The specific odds ratios are estimates of the effect of each study agent separately with or without the other study agent. All 
odds ratios have been adjusted for the presence or absence of shock. An odds ratio of more than 1 indicates increased mortality associated 
with the study agent. P = 0.49 for the test of interaction between antioxidants and glutamine.
† No adjustment was made to account for the two interim analyses or multiplicity of tests. Since the protocol specified a nominal significance 
level of 0.044 at the final analysis to account for the two interim analyses, the primary outcome did not reach formal significance for either 
intervention.
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have a significant effect on the outcomes of organ 
failure (Table 3 in the Supplementary Appendix) 
or infections (Table 4 in the Supplementary Ap-
pendix). Antioxidant supplementation as compared 
with no antioxidants did not have a significant 
effect on any secondary outcome (Table 3, and 
Tables 3 and 4 in the Supplementary Appendix).
Adverse Events
A total of 52 serious adverse events were reported 
in 46 patients; 4 were considered to be potentially 
related to study supplements. There were no sig-
nificant differences in rates of serious adverse 
events across groups (P = 0.83) (Table 5 in the Sup-
plementary Appendix). The frequency of high urea 
levels (>50 mmol per liter) was higher among pa-
tients who received glutamine than among those 
who did not (13.4% vs. 4.0%, P<0.001).
Laboratory Substudy
Baseline median plasma glutamine and selenium 
levels were within normal limits in 66 substudy 
patients (Fig. 2 and Table 6 in the Supplementary 
Appendix). Glutamine supplementation as com-
pared with no glutamine was associated with a 
significant increase in plasma glutamine levels 
on both day 4 and day 7 of the ICU stay (P<0.001 
for both comparisons). Antioxidant supplemen-
tation as compared with no antioxidants was as-
sociated with a significant increase from base-
line in plasma selenium levels on days 4 and 7 of 
the ICU stay (P<0.001 for both comparisons). How-
ever, median selenium levels remained within 
normal ranges in both groups at all time points.
Discussion
In this international, randomized, blinded trial 
involving critically ill patients with multiorgan 
failure, a nonsignificant increase in 28-day mor-
tality and significant increases in in-hospital and 
6-month mortality were observed with the use of 
glutamine. No effect of glutamine was observed 
on any other outcome. Antioxidant supplementa-
tion was not associated with any effect on study 
outcomes. In our prespecified subgroup analyses, 
we did not identify any indication of benefit or 
harm in the various patient subgroups examined.
The mechanism whereby glutamine may cause 
harm is unknown. However, several factors may 
account for the discrepancy between the results 
of our study and previous findings. First, prior in-
dications of benefit have emerged from the meta-
analysis of smaller, less methodologically robust 
trials.6 Second, in contrast to patients in previ-
ous studies in the ICU setting, patients in our 
trial received the highest dose of glutamine pre-
0.7 1.0 2.01.5 3.0
No Glutamine
Better
Glutamine
Better
All patients
No. of organ failures on presentation
2
>2
APACHE II score
≤Median
>Median
Admission diagnosis
Sepsis
Other
Age 
<55 yr
55 to <65 yr
65 to <75 yr
≥75 yr
Charlson comorbidity index score
0–1
>1
Odds Ratio (95% CI)
Odds Ratio (95% CI)
Subgroup
0.5
0.7 1.0 2.01.5 3.00.5
A Glutamine
No Antioxidants
Better
Antioxidants
Better
All patients
No. of organ failures on presentation
2
>2
APACHE II score
≤Median
>Median
Admission diagnosis
Sepsis
Other
Age 
<55 yr
55 to <65 yr
65 to <75 yr
≥75 yr
Charlson comorbidity index score
0–1
>1
Subgroup
B Antioxidants
Figure 2. Prespecified Subgroup Analyses of Death at 28 Days, According to 
Study Group.
Odds ratios and 95% confidence intervals are shown for the primary outcome 
in each prespecified subgroup. Higher Acute Physiology and Chronic Health 
Evaluation II (APACHE II) scores indicate greater disease severity. CI denotes 
confidence interval.
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scribed for critically ill patients (i.e., 30 g per day 
more than the maximal dose used in other stud-
ies). Third, we provided both intravenous and 
enteral supplementation, whereas prior trials used 
either the intravenous or enteral route exclusive-
ly. Fourth, we targeted critically ill patients with 
multiorgan failure, the majority of whom were in 
shock, whereas previous studies typically exclud-
ed such patients. Fifth, we initiated treatment 
with the study supplements within 24 hours after 
admission to the ICU, whereas in other studies, 
supplements were administered later in the 
course of critical illness, when parenteral nutri-
tion was required. Finally, most of our patients 
received enteral nutrition; in contrast, patients 
in prior trials received parenteral nutrition. The 
rationale for our study design reflected the view 
that glutamine is essential in critical illness be-
cause of rapid depletion of plasma glutamine 
levels; furthermore, lower plasma glutamine levels 
(<420 μmol per liter) have been associated with 
increased mortality.14 As such, we hypothesized 
that critically ill patients with organ dysfunction 
would be most likely to have low plasma gluta-
mine levels and poor clinical outcomes and 
would therefore benefit the most from supple-
Table 3. Clinical Outcomes in All 1218 Study Patients.
Variable Glutamine No Glutamine P Value Antioxidants No Antioxidants P Value
Death — no. of patients/total no. (%)
At day 28 198/611 (32.4) 165/607 (27.2) 0.05* 190/617 (30.8) 173/601 (28.8) 0.48
At day 14 157/611 (25.7) 129/607 (21.3) 0.07 154/617 (25.0) 132/601 (22.0) 0.23
In hospital 227/611 (37.2) 188/607 (31.0) 0.02 216/617 (35.0) 199/601 (33.1) 0.51
At 6 mo† 259 (43.7) 218 (37.2) 0.02 242 (40.4) 235 (40.6) 0.87
Time from randomization to final discontinuation 
of mechanical ventilation and alive — days‡
Median 11.0 8.7 0.03 9.1 10.5 0.67
Interquartile range 4.0–undefined 3.9–58.8 3.9–undefined 4.0–undefined
Time from randomization to discharge alive from 
ICU — days‡
Median 17.1 13.1 0.03 15.1 14.0 0.34
Interquartile range 7.3–undefined 7.1–undefined 7.2–undefined 7.2–undefined
Time from randomization to discharge alive from 
hospital — days‡
Median 51.0 40.1 0.04 43.8 42.7 0.39
Interquartile range 17.9–undefined 16.3–undefined 18.0–undefined 16.2–undefined
Hospital length of stay — days§
Median 16.0 17.1 0.15 16.9 16.6 0.97
Interquartile range 7.9–33.9 8.4–36.1 8.0–36.2 8.1–33.0
ICU length of stay — days§
Median 8.4 8.9 0.62 8.4 8.9 0.87
Interquartile range 4.4–16.0 5.1–15.3 4.6–15.3 5.1–15.8
Time from randomization to final discontinuation 
of mechanical ventilation — days§
Median 6.1 5.9 0.71 6.0 6.1 0.69
Interquartile range 2.8–12.8 2.9–11.9 2.8–11.8 2.9–12.7
* A P value of less than 0.044 was considered to indicate statistical significance.
† The number of deaths at 6 months was estimated by means of the Kaplan–Meier method, and these numbers are slightly higher than the 
result of dividing the number of deaths by the number of randomly assigned patients because some patients were lost to follow-up (i.e., 
their data were censored) within 6 months after randomization.
‡ In this category, death was considered a competing risk for discharge, so that patients who died before (or within 24 hours after) discharge 
remained undischarged forever. Interquartile ranges are undefined because more than 25% of patients died before discharge.
§ In this category, death was considered as discharge for patients who died before discharge. 
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mentation. However, we did not consistently 
find a deficiency of glutamine in the substudy 
involving 66 patients. Before our trial, we per-
formed a dose-finding study15 to evaluate the 
safety of this dosing strategy, but the design and 
small size of the earlier study made it insensitive 
to the possibly harmful effects that were identi-
fied in this larger trial.
With respect to antioxidant supplementation, 
our trial showed no effect overall or in any sub-
group. This finding may reflect the true lack of 
usefulness of antioxidants; alternatively, it may be 
due to the characteristics of the study population 
or to the dose and method of administration in 
this trial. The laboratory substudy of North 
American patients did not reveal the selenium 
deficiency consistently observed in European and 
South American trials of selenium status in criti-
cally ill and healthy persons.16,17 These differ-
ences may reflect the considerable depletion of 
selenium in soil observed in parts of Europe but 
not throughout North America.18 We may have 
prescribed an insufficient dose of selenium or used 
an ineffective dosing schedule, since a higher-than-
normal level of selenium in the blood may be as-
sociated with the best outcome19 and an initial 
bolus of selenium might have been more effective 
than the continuous administration we used.20
The strengths of this study include the ran-
domized and blinded design, rigorous determi-
nation and adjudication of infection, and inten-
tion-to-treat analysis, all of which augment the 
internal validity of the trial. The high rate of 
adherence to trial interventions, large number of 
patients, and enrollment in ICUs in North Amer-
ica and Europe bolster the external validity.
In conclusion, this trial showed that the early 
administration of glutamine in critically ill pa-
tients with multiorgan failure was harmful. The 
observation that the majority of these patients did 
not have glutamine deficiency early in the course 
of their critical illness challenges the prevailing 
concept that glutamine is an essential nutrient that 
is deficient in critically ill patients and requires 
immediate supplementation. We also conclude that 
antioxidant supplementation as provided in this 
trial conferred no therapeutic benefit.
Supported by the Canadian Institutes of Health Research.
Disclosure forms provided by the authors are available with 
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